PTC Therapeutics (PTCT) to Release Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) is anticipated to release its earnings data after the market closes on Thursday, February 27th. Analysts expect PTC Therapeutics to post earnings of ($1.12) per share and revenue of $248.99 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

PTC Therapeutics Stock Performance

Shares of PTCT traded up $0.31 during trading hours on Friday, hitting $50.69. 423,037 shares of the stock were exchanged, compared to its average volume of 686,683. The stock's 50-day moving average price is $46.67 and its two-hundred day moving average price is $41.49. PTC Therapeutics has a 12-month low of $24.00 and a 12-month high of $54.16. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -8.53 and a beta of 0.62.

Insider Buying and Selling

In other news, CEO Matthew B. Klein sold 8,279 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $45.16, for a total value of $373,879.64. Following the completion of the sale, the chief executive officer now directly owns 217,528 shares of the company's stock, valued at $9,823,564.48. This trade represents a 3.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Neil Gregory Almstead sold 1,300 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $65,130.00. Following the transaction, the insider now directly owns 101,931 shares in the company, valued at approximately $5,106,743.10. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 218,590 shares of company stock worth $11,264,023. Corporate insiders own 5.50% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Barclays boosted their target price on PTC Therapeutics from $45.00 to $56.00 and gave the stock an "equal weight" rating in a report on Tuesday, December 3rd. The Goldman Sachs Group boosted their price objective on PTC Therapeutics from $32.00 to $42.00 and gave the stock a "sell" rating in a research note on Wednesday, December 4th. Robert W. Baird raised their target price on PTC Therapeutics from $52.00 to $70.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 3rd. Morgan Stanley upgraded shares of PTC Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $45.00 to $67.00 in a report on Friday, December 13th. Finally, Cantor Fitzgerald upped their price objective on PTC Therapeutics from $76.00 to $113.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, PTC Therapeutics has a consensus rating of "Hold" and a consensus price target of $58.85.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.